Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.

Takeuchi, Tsutomu; van Vollenhoven, Ronald; Ueki, Yukitaka; Atsumi, Tatsuya; Meerwein, Sebastian; Bu, Xianwei; Hirata, Kazuya; Strand, Vibeke

doi:10.1093/mr/roag031

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.

2026-08-31, Modern rheumatology (10.1093/mr/roag031) (online)
Tsutomu Takeuchi, Ronald van Vollenhoven, Yukitaka Ueki, Tatsuya Atsumi, Sebastian Meerwein, Xianwei Bu, Kazuya Hirata, and Vibeke Strand (?)

To evaluate the long-term (5-year) efficacy and safety of upadacitinib monotherapy compared with methotrexate (MTX) monotherapy in Japanese patients with rheumatoid arthritis who were included in the Phase 3 SELECT-EARLY study.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: Long-term efficacy and safety through 5 years in the SELECT-EARLY study.